We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Non-invasive Test for Gastroparesis Developed for Routine Diagnostic Use

By Biotechdaily staff writers
Posted on 06 Jun 2007
A non-invasive test for gastroparesis, a chronic stomach condition characterized by nausea, vomiting, and abdominal pain, is now available for routine clinical diagnostic use.

The University of Kansas Hospital (Kansas City, USA) is one of the first in the United States to offer the SmartPill pH.p Capsule as a standard clinical test. More...
SmartPill, manufactured by SmartPill Corp. (Buffalo, NY, USA) is an ingestible, wireless capsule that measures pressure, pH, and temperature as it transits the gastrointestinal (GI) tract. This information is used to provide gastric emptying time, combined small and large bowel transit time, total transit time, pressure contraction patterns from the antrum and duodenum, and motility indices.

The capsule, which is somewhat larger than a multi-vitamin (26 mm x 13 mm), is administered in a physician's office. Since the SmartPill test is ambulatory, the patient is free to continue with his normal routine during the course of the assay. As the capsule passes through the GI tract, it transmits data to a data receiver worn by the patient. Once the single-use capsule has passed from the body, the patient returns the data receiver to the physician, who then downloads the collected data to a personal computer. The physician then uses a dedicated software package to analyze and display the data. Test results in both graphic and report formats are available within a few minutes.

While SmartPill in its present form cannot replace procedures such as endoscopy and colonoscopy, it may be used instead of gastric-emptying scintigraphy, which exposes a patient to radiation, and manometry, which involves the use of pressure catheters, inserted through the mouth and/or rectum.

"Some gastroparesis patients cannot really leave their house because of their problems. Often, these patients are losing weight because of limited nutritional intake,” explained Dr. Richard McCallum, professor of gastroenterology at the University of Kansas Hospital. "This new technology will allow us to give these patients the treatment they need much sooner and with a non-invasive safe and well-tolerated test with standardized results for better patient outcomes.”


Related Links:
University of Kansas Hospital
SmartPill

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.